Agilent Technologies plans to double its manufacturing capacity of therapeutic nucleic acids.
The new nucleic acid contract development and manufacturing services offer superior customer service, the highest quality oligo API material, and cGMP (Current Good Manufacturing Practices) to produce high-volume oligos efficiently and cost-effectively from early-stage clinical development to commercialisation. Current manufacturing facilities produce siRNA, antisense molecules, and CRISPR guide RNA molecules.
The new project will bring more than 160 life science jobs contributing to the fast-growing biotechnology ecosystem and increase U.S. manufacturing for active pharmaceutical ingredients (API) that are used to treat a wide range of illnesses, such as cancer, infectious diseases, and cardiovascular diseases.
The construction is expected to complete by the end of 2026.